Literature DB >> 29669671

Drug-induced eosinophilia.

Christine Rauscher1, Allison Freeman2.   

Abstract

BACKGROUND: Drug reactions have been associated with increased blood eosinophil levels.
OBJECTIVE: To review clinical characteristics, the diagnosis, and the management of drug-induced eosinophilia.
METHODS: Pertinent articles were selected and reviewed in relation to a case presentation of drug-induced eosinophilia.
RESULTS: A case of asymptomatic eosinophilia in the setting of acetylsalicylic acid (aspirin) use was presented, followed by discussion of the clinical characteristics, diagnosis, and management of drug-induced eosinophilia. Clinical pearls and pitfalls were reviewed for the practicing allergist, clinical immunologist, and fellow-in-training.
CONCLUSION: Drug-induced eosinophilia is a diagnosis of exclusion. Although most cases of drug-induced eosinophilia are asymptomatic, one study showed an increased rate of hypersensitivity reactions in patients with higher eosinophil counts and earlier onset of eosinophilia.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29669671     DOI: 10.2500/aap.2018.39.4120

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  3 in total

1.  The Floralia: A festive time for Romans and a demanding time for the allergist/immunologist.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2018-05-01       Impact factor: 2.587

2.  Eosinophilic myocarditis presenting with hypoactive delirium and cardioembolic stroke.

Authors:  Ka Hong Chan; Paul Gibson
Journal:  CMAJ       Date:  2019-10-21       Impact factor: 8.262

3.  Association of antipsychotic use with raised eosinophil count.

Authors:  Konstantinos Tsamakis; Christoph Mueller; Ioannis Hortis; Maria Kallergi; Ioannis Tolos; Evangelos Alevyzakis; Nikolaos Siafakas; Andreas Ouranidis; Dimitrios Tsiptsios; Stylianos Kympouropoulos; Demetrios A Spandidos; Nikolaos Smyrnis; Emmanouil Rizos
Journal:  Exp Ther Med       Date:  2021-03-19       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.